Academic literature on the topic 'Golder Associates Inc'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Golder Associates Inc.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Golder Associates Inc"
1
Paterson, Robert K., and Anastasia Telesetsky. "Heritage Inc.: A Mini-Symposium on Heritage Protection and Private Actors. Held at the Faculty of Law, University of British Columbia, Vancouver, Canada, 16 March 2012." International Journal of Cultural Property 19, no. 4 (November 2012): 549–71. http://dx.doi.org/10.1017/s0940739112000355.
Full textAbstract:
In response to the emerging phenomenon of the role of nonstate actors in heritage protection and preservation, a one-day symposium took place on 16 March 2012 in the new Allard Hall building of the Faculty of Law at the University of British Columbia in Vancouver, Canada. The conference was officially opened by Dean of Law, Professor Mary Anne Bobinski and received financial support from the University of British Columbia, Faculty of Law Conference Fund; the Pacific Northwest Canadian Studies Consortium; and Golder Associates Ltd. The conference brought together seven experts from both academia and practice to discuss contemporary practices and emerging legal and sociological trends in heritage protection by private actors.
2
Suzuki, Keiji, Naomi Yasuda, Fumio Suzuki, Osamu Nikaido, and Masami Watanabe. "Trisomy of chromosome 9q: Specific chromosome change associated with tumorigenicity during the process of X-ray-induced neoplastic transformation in golden hamster embryo cells." International Journal of Cancer 44, no. 6 (December 15, 1989): 1057–61. http://dx.doi.org/10.1002/ijc.2910440620.
Full text
3
Demakos, Erin P., Lewis R. Silverman, Moira E. Lawrence, Thomas J. McKearn, Scott Megaffin, Rita Percy, and Michael E. Petrone. "Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents." Blood 124, no. 21 (December 6, 2014): 1287. http://dx.doi.org/10.1182/blood.v124.21.1287.1287.
Full textAbstract:
Abstract Background : The incidence of myelodysplastic syndromes (MDS) - a heterogeneous group of malignant myeloid stem cell disorders - increases with age and commonly affects older people. The prevalence of MDS in the US has been constantly rising as a result of increasing longevity of the overall population. Analyses of healthcare claims data using associated medical claims information (ICD-9-CM diagnosis codes) are a common way to estimate the number patients (pts) receiving care in specific disease states. We examined the total of unique US claims for MDS submitted over a 3-year period and also analyzed the claims according to type of treatment. Methods : We conducted a retrospective cohort study of patients (pts) with an MDS-associated medical claim (ICD-9-CM diagnosis code 238.7x) in the observation (OB) period (calendar years 2009-2011). In each year of the OB period, pts were classified according to type of treatment: watch and wait (ie, receiving no drug therapy) or interventional treatment [ie, supportive care treatment with erythropoietin stimulating agents (ESA) or growth factors (GF) and active drug treatment (ie, the hypomethylating agents (HMA) azacitidine (AZA) and decitabine (DEC) and the immunomodulating agent lenalidomide (REV)]. A subgroup of newly diagnosed MDS pts was also identified in Years 2 and 3, but this group was not included in Year 1 of the OB period (calendar year 2009); this group of new-to-treatment patients had a claim for MDS in Years 2 and 3 of the OB period. MDS incidence rates were then determined within Years 2 and 3 of the OB period for this group. The total number of physicians treating pts coded for MDS was also collected. Results : We identified more than 100,000 unique pts with an MDS-associated claim in each of the 3 years of the OB period. Our calculated incidence of newly treated MDS pts (34,000) in Years 2 and 3 is consistent with recently reported estimates (Cogle et al, Blood 2011; Goldberg et al, J Clin Oncol 2010) but higher than the SEER database. Over the 3-year OB period, the number of diagnosed and treated MDS pts grew year on year and grew at a slower rate than that of the US population. Watch-and-wait is the mainstay treatment for 47% of MDS pts. We found that 6000 pts per month are treated with an HMA by 2100 physicians, or 2.8 pts per physician and 14,000 pts receive therapy for MDS comprised of ESA, GF, AZA, DEC or REV per year. AZA and DEC were the predominant HMA treatments prescribed for higher-risk MDS. Approximately 30% of HMA-treated reached the target number of 6 cycles. HMA therapies were used in 13.1% of pts. A larger percentage of the AZA- and DEC-treated pts (69.1%) stopped therapy before reaching the target number of doses, with approximately 32% of pts who initiated therapy dropping out after the first cycle. Conclusions : The total number of pts coded for MDS-associated ICD-9 billing in the US each year is substantial. The estimated incidence of 34,000 patients per year with MDS in the US in 2010 and 2011 is similar to results found in other epidemiological databases. The majority of pts are not treated with the optimal number of cycles with an HMA. The average physician treats only a limited number of pts with MDS, which may influence treatment decisions. These data suggest a need for further educational efforts to optimize care with additional insight into past population-based estimates of diagnosis and treatment (Cogle et al, Blood 2011; Goldberg et al, J Clin Oncol 2010). The data showing early discontinuation or failure of HMA therapy accentuates the poor prognosis of patients post-HMA, who have a predicted median survival of 4-6 months (Prebet et al, J Clin Oncol 2011). These data may serve to better inform the medical community of the unmet need of pts who are not successfully treated with first-line MDS therapies, underscoring the need for optimization of care and the need for additional agents beyond those currently available. Table HMA Cycle and Administration Metrics per Line of Therapy Treatment Metric Moving Annual Total 2010 2011 2012 Dacogen Median number of cycles 4-day admin schedule 5-day admin schedule 3.00 14.7% 64.0% 4.00 11.4% 67.6% 3.00 12.6% 66.2% Vidaza Median number of cycles 5-day admin schedule 7+ day admin schedule 4.00 47% 20% 4.00 49% 20% 4.00 46% 20% Disclosures Demakos: Onconova Therapeutics, Inc: Consultancy. Silverman:Onconova Therapeutics, Inc: Consultancy. Lawrence:Onconova Therapeutics, Inc. : Employment. McKearn:Onconova Therapeutics, Inc. : Employment. Megaffin:Onconova Therapeutics, Inc. : Employment. Percy:Onconova Therapeutics, Inc. : Employment. Petrone:Onconova Therapeutics, Inc. : Employment, Stock Options Other.
4
Kandane-Rathnayake, R., W. Louthrenoo, A. Hoi, V. Golder, Y. H. Chen, S. F. Luo, Y. J. Jan Wu, et al. "POS0028 DEFINING THE PREVALENCE OF UNMET NEED IN SLE: DATA FROM A LARGE MULTINATIONAL LONGITUDINAL SLE COHORT." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 218–19. http://dx.doi.org/10.1136/annrheumdis-2021-eular.938.
Full textAbstract:
Background:The recent prospectively validated definition of the lupus low disease activity state (LLDAS) allows characterisation of patients not achieving a treatment goal, providing impetus for an analysis of unmet needs in SLE using formal definitions. Other recently described definitions of high disease burden include disease activity over time, high disease activity status (HDAS) episodes, and the combination of high disease activity, serological activity and glucocorticoid (GC) use (HDAS+SA+GC).Objectives:To determine the prevalence of formal categories of unmet need, and the association of these with adverse outcomes, in SLE.Methods:Data from a 13-country longitudinal SLE cohort (ACR/SLICC criteria) were collected between 2013 and 19 using standard templates. Unmet need was defined as (i) patients never attaining LLDAS defined as in Golder et al., 2019 [1], (ii) having persistently active disease (time adjusted mean SLEDAI-2K (AMS) > 4), (iii) ever exhibiting high disease activity status (HDAS; SLEDAI-2K ≥10[2]), or (iv) ever exhibiting all of SLEDAI≥10, serological activity, and glucocorticoid use (HDAS+SA+GC)[3]. Health-related quality of life (HRQoL) was assessed using SF36 (v2) surveys and damage accrual using SLE Damage Index (SDI).Results:3,384 SLE patients were followed for 30,313 visits over median [IQR] 2.4 [0.4, 4.3] years. 53% of all visits were not in LLDAS; 813 patients (24%) never achieved LLDAS during observation. Median AMS was 3.0 [1.4, 4.9] and 34% of patients had AMS > 4 throughout the study. 25% of patients had at least one episode of HDAS, representing 8% of visits. 702 patients (21%) had at least one episode of HDAS+SA+GC, representing 8% of visits. Each of never-LLDAS, AMS>4, ever-HDAS, and ever-HDAS+SA+GC were associated with significantly greater number of physician visits, higher mean glucocorticoid dose, lower HRQoL and higher mortality. 31%, 58% and 83% of never-LLDAS, AMS>4, and ever-HDAS patients respectively were also HDAS+SA+GC on at least one occasion.Conclusion:Data from a multinational longitudinal SLE cohort indicate that unmet need, defined by LLDAS-never, AMS>4, HDAS, or HDAS+SA+GC, is prevalent in SLE, and that these definitions are associated with poor outcomes.References:[1]Golder, V., et al., Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. The Lancet Rheumatology, 2019. 1(2): p. e95-e102.[2]Koelmeyer, R., et al., High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. Lupus Sci Med, 2020. 7(1).[3]van Vollenhoven, R.F., et al., Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Annals of the Rheumatic Diseases, 2012. 71(8): p. 1343-1349.Acknowledgements:The APLC acknowledges all the Data Collectors and Patients for their valuable contributions to research.Disclosure of Interests:Rangi Kandane-Rathnayake: None declared, Worawit Louthrenoo: None declared, Alberta Hoi Consultant of: Abbvie and GSK, Grant/research support from: AstraZeneca, GSK, BMS, Janssen, and Merck Serono, Vera Golder: None declared, Yi-Hsing Chen Speakers bureau: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Lilly, AstraZeneca, Sanofi, MSD, Guigai, Astellas, Inova Diagnostics, UCB, Agnitio Science Technology, United Biopharma, Thermo Fisher, Consultant of: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Lilly, AstraZeneca, Sanofi, MSD, Guigai, Astellas, Inova Diagnostics, UCB, Agnitio Science Technology, United Biopharma, Thermo Fisher, Gilead, Grant/research support from: Pfizer, Norvatis, BMS, Abbevie, Johnson & Johnson, Roche, Sanofi, Guigai, Roche, Boehringer Ingelheim, UCB, MSD, Astra-Zeneca, Astellas, Gilead, Shue Fen Luo: None declared, Yeong-Jian Jan Wu Speakers bureau: Pfizer, Lilly, Novartis, Abbvie, Aisha Lateef: None declared, Jiacai Cho: None declared, Laniyati Hamijoyo Speakers bureau: Pfizer, Novartis, Abbot, Chak Sing Lau Shareholder of: Pfizer, Sanofi, and Janssen, Sandra Navarra Speakers bureau: Pfizer, Johnson & Johnson, Novartis, Astellas, Grant/research support from: Astellas, Johnson & Johnson, Leonid Zamora: None declared, Zhanguo Li Speakers bureau: Eli, Lilly, Novartis, GSK, AbbVie, Paid instructor for: Pfizer, Roche, Johnson., Consultant of: Lilly, Pfizer, Grant/research support from: Pfizer, Yuan An: None declared, Sargunan Sockalingam Speakers bureau: Pfizer, Roche, Novartis, Grant/research support from: Roche and Novartis, Yasuhiro Katsumata Speakers bureau: Chugai Pharmaceutical Co., Ltd., Glaxo-Smithkline K.K., and Sanofi K.K., masayoshi harigai Speakers bureau: AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc.,Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd., Consultant of: AbbVie, Boehringer-ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co.,Ltd. and Teijin Pharma., Grant/research support from: AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc.,Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekiui Medical, Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd., Yanjie Hao: None declared, Zhuoli Zhang Speakers bureau: Norvatis, GSK, Pfizer, Jun Kikuchi: None declared, Tsutomu Takeuchi Speakers bureau: AbbVie AYUMI Pharmaceutical Corp. Bristol-Myers Squibb Chugai Pharmaceutical Co, Ltd. Daiichi Sankyo Co., Ltd. Eisai Co., Ltd. Eli Lilly Japan, Gilead Sciences, Inc. Mitsubishi-Tanabe Pharma Corp. Pfizer Japan Inc. Sanofi K.K., Consultant of: Astellas Pharma, Inc. Chugai Pharmaceutical Co, Ltd. Eli Lilly Japan, Mitsubishi-Tanabe Pharma Corp., Grant/research support from: AbbVie, Asahikasei Pharma Corp. Chugai Pharmaceutical Co, Ltd. Mitsubishi-Tanabe Pharma Corp. Sanofi K.K., BMDB Basnayake: None declared, Fiona Goldblatt: None declared, Madelynn Chan Speakers bureau: AbbVie, Novartis, Consultant of: Pfizer, Eli-Lilly, Kristine Ng Speakers bureau: Abbvie, Novartis, Janssen, Sang-Cheol Bae: None declared, Shereen Oon: None declared, Sean O’Neill Consultant of: GSK, Kathryn Gibson Speakers bureau: UCB, Consultant of: Novartis, Janssen, Grant/research support from: Novartis, Sunil Kumar: None declared, Nicola Tugnet: None declared, Yoshiya Tanaka Speakers bureau: Daiichi-Sankyo, Eli Lilly, Novartis, YL Biologics, Bristol-Myers, Eisai, Chugai, Abbvie, Astellas, Pfizer, Sanofi, Asahi-kasei, GSK, Mitsubishi-Tanabe, Gilead, Janssen, Grant/research support from: Abbvie, Mitsubishi-Tanabe, Chugai, Asahi-Kasei, Eisai, Takeda, Daiichi-Sankyo, Mandana Nikpour Speakers bureau: Actelion, GSK, Janssen, Pfizer, UCB, Paid instructor for: UCB, Consultant of: Actelion, Boehringer Ingelheim, Certa Therapeutics, Eli Lilly, GSK, Janssen, Pfizer, UCB, Grant/research support from: Actelion, Astra Zeneca, BMS, GSK, Janssen, UCB, Eric F. Morand Speakers bureau: AstraZeneca, Paid instructor for: Eli Lilly, Consultant of: AstraZeneca, Amgen, Biogen, BristolMyersSquibb, Eli Lilly, EMD Serono, Genentech, Janssen, Grant/research support from: AstraZeneca, BristolMyersSquibb, Eli Lilly, EMD Serono, Janssen.
5
Goldberg, Stuart L., Yun Su, Candace Gunnarsson, William D. Irish, Michael Ryan, Mabel Woloj, Roxanne Ferdinand, and Mark Shapiro. "The Effect of Vascular Occlusive Events on Discontinuation and Cost of Care in Patients Treated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia." Blood 126, no. 23 (December 3, 2015): 2797. http://dx.doi.org/10.1182/blood.v126.23.2797.2797.
Full textAbstract:
Abstract Introduction: Vascular occlusive events (VOE) are an important late complication among chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI). This study examines the impact of VOE on risk of discontinuation and cost of care among patients treated with TKIs outside of research protocol settings. Methods: TKI treatment episodes for adult patients with CML diagnoses from 1/1/2009 to 1/31/2015 were identified in a large commercial insurance claims, Medicaid, and Medicare database in the US. Patients were required to have ≥6 months of enrollment prior to each TKI episode and ≥1 medical or pharmacy claims on or after the first CML diagnosis date for one of the TKIs: imatinib (IM), dasatinib (DAS), nilotinib (NIL), bosutinib (BOS), and ponatinib (PON). VOE include one or more of the following: myocardial infarction, congestive heart failure, thrombotic events, acute coronary syndrome, peripheral vascular, cerebrovascular, or coronary artery diseases. Cox proportional hazard model was used to evaluate time to discontinuation, as measured from the start date of each TKI episode to the earliest of the following: 1) switched TKI treatment, 2) stopped taking TKI defined as no refills for 90 days past end of drug supply, 3) had a bone marrow or stem cell transplant, or 4) death. Gamma log-link regression was used to model total all-cause healthcare costs for each treatment episode. Costs were measured in 2014 US dollars per patient per month (PPPM), and included patient out-of-pocket costs, insurance-paid costs for CML drugs, other outpatient prescriptions, inpatient services, emergency room visits, office visits, and other outpatient services. For both models, first occurrence of a treatment-emergent VOE within the TKI episode was included as a time-dependent variable. Other independent explanatory variables for the models included: age, gender, baseline Charlson Comorbidity Index from the National Cancer Institute (CCI NCI), type of TKI agent, and line of therapy. Results: A total of 4,541 TKI treatment episodes (IM 1,982; DAS 1,321; NIL 1,059; BOS 114; PON 65) for CML were identified (mean age: 53.1 years and males: 51.9%). IM was the most commonly used first line TKI (54%). DAS was used 1st line in 26% and 2nd line in 33%. NIL was used 1st line in 19% and 2nd line in 25%. BOS and PON were predominately used in 3rd line or later. 947 (20.9%) VOEs occurred in all treatment episodes with 371 (21.1%), 357 (22.3%), and 219 (18.6%) occurring in first, second, and third plus lines, respectively. Occurrence of a VOE was associated with a significantly increased risk of TKI discontinuation (adjusted hazard ratio: 1.4 [1.2-1.6]). Compared to BOS, adjusted risk of discontinuation was not significantly different for treatment episodes using IM, DAS, or NIL, but was significantly higher for PON (Table 1). Cost of care for patients experiencing a VOE was also significantly higher (mean $3,702 PPPM higher) than for patients not experiencing an event (p=0.0454). Treatment with PON was independently associated with significantly higher cost of care compared to BOS (p=0.0026; Table 1). Conclusions: Vascular Occlusive Events appear to be significantly associated with a higher risk of discontinuation and increased health care costs. Additionally, compared to BOS, PON appears to be independently associated with a significantly higher risk of discontinuation and higher costs. BOS appears comparable to IM, DAS, and NIL in duration of treatment and cost of care. It will be important to determine if factors other than VOE might underlie the higher discontinuations and costs observed with PON. Sensitivity analyses should also be conducted with deaths and transplants as censoring or true treatment discontinuation events. Sponsorship Statement: This study was sponsored by Pfizer, Inc. Disclosures Goldberg: Pfizer: Research Funding; Novartis: Research Funding, Speakers Bureau; BMS: Research Funding, Speakers Bureau; Ariad: Research Funding, Speakers Bureau; COTA: Employment, Equity Ownership, Other: Leadership, Stock. Su:Pfizer Inc: Employment, Other: Stock Ownership. Gunnarsson:Pfizer Inc: Consultancy. Irish:Pfizer Inc: Consultancy; Alexion: Consultancy; BMS: Consultancy; Novartis: Consultancy; Sanofi: Consultancy; Astellas: Consultancy. Ryan:Pfizer Inc: Consultancy. Woloj:Pfizer Inc: Employment, Other: Stock Ownership. Ferdinand:Pfizer Ltd: Employment. Shapiro:Pfizer Inc: Employment, Other: Stock Ownership.
6
Martínez Zubiaur, Y., M. Quiñones, D. Fonseca, J. L. Potter, and D. P. Maxwell. "First Report of Tomato yellow leaf curl virus Associated with Beans, Phaseolus vulgaris, in Cuba." Plant Disease 86, no. 7 (July 2002): 814. http://dx.doi.org/10.1094/pdis.2002.86.7.814d.
Full textAbstract:
Beans with yellow mosaic and/or leaf crumple symptoms were collected in three fields in the southern area of the province of Havana, Cuba in December 2001 and February 2002. DNA was extracted from the fresh bean leaves of 25 samples (1). Dot blot hybridization was performed at high stringency with a specific probe for Tomato yellow leaf curl virus (TYLCV). The specific probe was prepared by alkaline phosphatase labeling of the polymerase chain reaction (PCR) fragment amplified with primer pair, PTYIRv21/PTYIRc287, containing the intergenic region (IR) of TYLCV, and chemiluminescent hybridization was completed as described by the manufacturer (AlkPhos Direct Labeling and Detection Systems, Amersham Pharmacia Biotech Inc., Piscataway, NJ). Four of the samples had positive hybridization signals. PCR was performed with overlapping primers for TYLCV (2) with the DNA extract from sample 01–44, which gave a positive hybridization signal with the TYLCV probe, and a 2.8-kb fragment was obtained. This fragment was cloned in pGem T-Easy (pBeTY44) and partially sequenced. Greater than 96% nt identity was obtained for the 591 nt of the IR and 504 nt of the N-terminus of the Rep gene with TYLCV (GenBank Accession No. AF260331). Also, PCR was completed on 11 of the 25 samples with the degenerate primer pair PAL1v1978/PAR1c715 for DNA-A (3). Eight samples gave fragment sizes of 1.4 kb and one sample gave a fragment of 1.3 kb. The 1.3-kb fragment from sample number 01–50 was cloned in pGem T-Easy (pBeBG50) and partially sequenced. Pairwise nucleotide comparisons with Bean golden yellow mosaic virus (BGYMV, GenBank Accession No. M91604) were 95% for 719 nt of the N-terminus of the Rep gene. These results are consistent with the association of both TYLCV and BGYMV in beans and have important implications for future disease management strategies. References: (1) G. P. Accotto et al. Eur. J. Plant. Pathol. 106:179, 2000. (2) M. K. Nakhla et al. Plant Dis. 78:926, 1994. (3) M. Rojas et al. Plant Dis. 77:340, 1993.
7
Kandane-Rathnayake, R., W. Louthrenoo, S. F. Luo, Y. J. Wu, Y. H. Chen, V. Golder, A. Lateef, et al. "AB0384 MEDICATION USE IN SYSTEMIC LUPUS ERYTHEMATOSUS – DATA FROM A MULTICENTRE COHORT STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1492–93. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3007.
Full textAbstract:
Background:In the absence of evidence-based treatment guidelines, medication use in SLE is highly variable. Low rates of remission and lupus low disease activity state (LLDAS) suggest that suboptimal responses to standard medications, which include glucocorticoids (GC), anti-malarial (AM) drugs and immunosuppressive (IS) agents, are common. Understanding the utility of current medications will facilitate the selection of patients for advanced therapies as they emerge.Objectives:To examine medication use patterns in a large multicentre SLE cohort.Methods:We used 2013-18 data from the Asia Pacific Lupus Collaboration (APLC) cohort in which disease activity (SLEDAI-2K) and medication details were captured at every visit. LLDAS was defined as in Golderet al., 2019 (1). We examined the use of medication (med) categories (GC &/or AM &/or IS) by SLE disease activity and LLDAS at the visit level. Additionally, we performed Cox regression analyses to determine the time-to-discontinuation of meds stratified by SLE disease activity, ranked by time-adjusted mean SLEDAI-2K, and by percent-time spent in LLDAS.Results:We analysed data from 19,804 visits of 2,860 patients. We observed 8 med categories: no meds; GC, AM or IS only; GC+AM; GC+IS; AM+IS and GC+AM+IS (triple therapy). Triple therapy was the most frequent med pattern (32%); single agents were used in 21% of visits and biologicals in only 3%. Among visits where SLEDAI-2K was ≥10, triple therapy was used in 46%, with median [IQR] GC dose 10 [6, 24] mg/day; in contrast, among visits with SLEDAI-2K≤4 triple therapy was used in 28% (p<0.01). Patients in LLDAS received less combination therapy than those who were not in LLDAS.Med persistence (survival analysis) varied widely, with lowest survivals for IS. Patients with time-adjusted mean SLEDAI-2K ≥10 had lower discontinuation of GC and higher discontinuation of IS including azathioprine, leflunomide and cyclosporine (Table 1). In contrast, increased time in LLDAS was associated with reduced discontinuation of AM and azathioprine.GCAMISMPhMPhAAZAMTXCyALEFOverall med survival, days to 25% discontinuation (95%CI)1048(938, 1197)1267(1113, 1428)175(175, 182)387(252, 756)409(350, 476)525(219, 686)268(182, 350)329(190, 524)Univariable associations,HR (95% CI) p-valueDisease activity≤41.001.001.001.001.001.001.001.00>4 & <100.69 (0.56,0.84)p<0.0011.15 (0.92,1.44)0.20.92 (0.80,1.05)0.21.37 (0.78,2.42)0.31.16 (0.97,1.39)0.111.11 (0.72,1.71)0.61.26 (0.90,1.77) 0.181.88 (1.07,3.30) 0.03≥100.65 (0.35,1.21) 0.181.56 (0.94,2.59) 0.080.84 (0.45,1.57)0.61.92 (0.80,4.63)0.142.69 (1.86,3.91) p<0.0011.85 (0.92,3.71) 0.082.66 (1.36,5.21) 0.0041.62 (1.13,2.32)0.009LLDAS<50%1.001.001.001.001.001.001.001.00≥50%1.30 (1.09, 1.55)0.0030.67 (0.54, 0.84)<0.0011.22 (1.08, 1.40)0.0020.83 (0.44,1.57)0.60.83 (0.69, 1.00)0.0540.70 (0.46, 1.07)0.101.29 (0.92, 1.83)0.140.43 (1.5, 1.25)0.12Conclusion:In a large multicentre SLE cohort, most patients were receiving combination treatment. AM treatment survival was high and associated with low disease activity, GC survival was high and associated with high disease activity, while IS survival was low. Patients with high disease activity received more medication combinations but had reduced IS survival. These data suggest ongoing unmet need for improved medications for treatment of SLE.Reference:Golder, V., et al Lancet Rheum. 2019 1(2):e95-102Disclosure of Interests:Rangi Kandane-Rathnayake Grant/research support from: The APLC has received financial (non-restricted educational) grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen, EMD Serono, Eli Lilly and UCB for the LLDAS Validation Study., Worawit Louthrenoo: None declared, Shue Fen Luo: None declared, Yeong-Jian Wu Consultant of: Pfizer, Lilly, Novartis, Abbvie, Roche, Speakers bureau: Lilly, Novartis, Yi-Hsing Chen Grant/research support from: Taiwan Ministry of Science and Technology, Taiwan Department of Health, Taichung Veterans General Hospital, National Yang-Ming University, GSK, Pfizer, BMS., Consultant of: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Lilly, GSK, Astra& Zeneca, Sanofi, MSD, Guigai, Astellas, Inova Diagnostics, UCB, Agnitio Science Technology, United Biopharma, Thermo Fisher, Gilead., Paid instructor for: Pfizer, Novartis, Johnson & Johnson, Roche, Lilly, Astra& Zeneca, Sanofi, Astellas, Agnitio Science Technology, United Biopharma., Speakers bureau: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Lilly, GSK, Astra& Zeneca, Sanofi, MSD, Guigai, Astellas, Inova Diagnostics, UCB, Agnitio Science Technology, United Biopharma, Thermo Fisher, Gilead., Vera Golder: None declared, Aisha Lateef: None declared, Jiacai Cho: None declared, Sandra Navarra Speakers bureau: Astellas, Novartis, Pfizer, Johnson & Johnson, Abbvie, Leonid Zamora: None declared, Laniyati Hamijoyo Speakers bureau: Pfizer, Novartis, Tanabe, Abbot, Dexa Medica, Roche, Sargunan Sockalingam: None declared, Yuan An: None declared, Zhanguo Li: None declared, Yasuhiro Katsumata: None declared, masayoshi harigai Grant/research support from: AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., and Teijin Pharma Ltd. MH has received speaker’s fee from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Oxford Immuotec, Pfizer Japan Inc., and Teijin Pharma Ltd. MH is a consultant for AbbVie, Boehringer-ingelheim, Kissei Pharmaceutical Co., Ltd. and Teijin Pharma., Yanjie Hao: None declared, Zhuoli Zhang: None declared, Madelynn Chan: None declared, Jun Kikuchi: None declared, Tsutomu Takeuchi Grant/research support from: Eisai Co., Ltd, Astellas Pharma Inc., AbbVie GK, Asahi Kasei Pharma Corporation, Nippon Kayaku Co., Ltd, Takeda Pharmaceutical Company Ltd, UCB Pharma, Shionogi & Co., Ltd., Mitsubishi-Tanabe Pharma Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co. Ltd., Consultant of: Chugai Pharmaceutical Co Ltd, Astellas Pharma Inc., Eli Lilly Japan KK, Speakers bureau: AbbVie GK, Eisai Co., Ltd, Mitsubishi-Tanabe Pharma Corporation, Chugai Pharmaceutical Co Ltd, Bristol-Myers Squibb Company, AYUMI Pharmaceutical Corp., Eisai Co., Ltd, Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc., Novartis Pharma K.K., Pfizer Japan Inc., Sanofi K.K., Dainippon Sumitomo Co., Ltd., Fiona Goldblatt: None declared, Sean O’Neill: None declared, Chetan Karyekar Shareholder of: Johnson & Johnson, Consultant of: Janssen, Employee of: Janssen Global Services, LLC. Previously, Novartis, Bristol-Myers Squibb, and Abbott Labs., Jennifer H. Lofland Employee of: Janssen, Sang-Cheol Bae: None declared, Chak Sing Lau: None declared, Alberta Hoi: None declared, Mandana Nikpour: None declared, Eric F. Morand Grant/research support from: AstraZeneca, Consultant of: AstraZeneca, Speakers bureau: AstraZeneca
8
Zhu, Ke-Cheng, Meng Wu, Dian-Chang Zhang, Hua-Yang Guo, Nan Zhang, Liang Guo, Bao-Suo Liu, and Shi-Gui Jiang. "Toll-Like Receptor 5 of Golden Pompano Trachinotus ovatus (Linnaeus 1758): Characterization, Promoter Activity and Functional Analysis." International Journal of Molecular Sciences 21, no. 16 (August 18, 2020): 5916. http://dx.doi.org/10.3390/ijms21165916.
Full textAbstract:
Toll-like receptors (TLRs), as important pattern recognition receptors, represent a significant component of fish immune systems and play an important role in resisting the invasion of pathogenic microorganisms. The TLR5 subfamily contains two types of TLR5, the membrane form of TLR5 (TLR5M) and the soluble form of TLR5 (TLR5S), whose detailed functions have not been completely elucidated. In the present study, we first identified two genes, TLR5M (ToTLR5M) and TLR5S (ToTLR5S), from golden pompano (Trachinotus ovatus). The full-length ToTLR5M and ToTLR5S cDNA are 3644 bp and 2329 bp, respectively, comprising an open reading frame (ORF) of 2673 bp, encoding 890 amino acids, and an ORF of 1935 bp, encoding 644 amino acids. Both the ToTLR5s possess representative TLR domains; however, only ToTLR5M has transmembrane and intracellular TIR domains. Moreover, the transcription of two ToTLR5s was significantly upregulated after stimulation by polyinosinic:polycytidylic acid (poly (I:C)), lipopolysaccharide (LPS), and flagellin in both immune-related tissues (liver, intestine, blood, kidney, and skin) and nonimmune-related tissue (muscle). Furthermore, the results of bioinformatic and promoter analysis show that the transcription factors GATA-1 (GATA Binding Protein 1), C/EBPalpha (CCAAT Enhancer Binding Protein Alpha), and ICSBP (Interferon (IFN) consensus sequence binding protein) may play a positive role in moderating the expression of two ToTLR5s. Overexpression of ToTLR5M and ToTLR5S notably increases NF-κB (nuclear factor kappa-B) activity. Additionally, the binding assay revealed that two rToTLR5s can bind specifically to bacteria and pathogen-associated molecular patterns (PAMPs) containing Vibrio harveyi, Vibrio anguillarum, Vibrio vulnificus, Escherichia coli, Photobacterium damselae, Staphylococcus aureus, Aeromonas hydrophila, LPS, poly(I:C), flagellin, and peptidoglycan (PGN). In conclusion, the present study may help to elucidate the function of ToTLR5M/S and clarify their possible roles in the fish immune response to bacterial infection.
9
Goldberg, Aaron D., Robert H. Collins, Richard M. Stone, Roland B. Walter, Chatchada Karanes, Carlos E. Vigil, Eunice S. Wang, and Martin S. Tallman. "Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML." Blood 132, Supplement 1 (November 29, 2018): 1436. http://dx.doi.org/10.1182/blood-2018-99-117016.
Full textAbstract:
Abstract Background: Patients with AML harboring FLT3 mutations have poor clinical outcomes. Furthermore, FLT3 mutations frequently co-occur with other driver mutations, such as NPM1 with DNMT3A, WT1, and RUNX1, that are associated with poor prognosis. Crenolanib is a highly potent and specific type-I FLT3 inhibitor, which has shown promising safety and efficacy in combination with chemotherapy. Here we report the outcomes of newly diagnosed FLT3 mutated AML patients treated with crenolanib and intensive 7 + 3 based chemotherapy (NCT02283177) by baseline genomic profile. Methods: Patients were treated on clinical trial with 7+3 induction chemotherapy combined with crenolanib, consolidation with high-dose cytarabine (HiDAC) combined with crenolanib, and/or allo-HCT followed by crenolanib maintenance. Of 44 pts enrolled and treated, 36 had sequencing performed at baseline. The median survival follow-up for these patients was 20.7 months with data cut off July 25, 2018. A post hoc analysis was performed to assess the impact of genomic profile on patient outcomes using published data from the German-Austrian AML Study Group as a historical control. Results: Concurrent FLT3-ITD, NPM1, and DNMT3A mutations ("triple mutant") were present in 10 pts. These patients demonstrated improved OS with crenolanib treatment compared with historical controls. Similarly, patients with FLT3-ITD and WT1 mutations (n = 6) showed dramatically improved outcomes, with no deaths occurring by 18 months. Patients with FLT3 (ITD or TKD) and RUNX1 mutations (n = 10) also had improved OS. Conclusions: This analysis suggests that adding a potent pan-FLT3 inhibitor can overcome the poor prognostic implication of adverse mutations co-occurring with mutated FLT3. These data support the combination of crenolanib with chemotherapy to improve the overall outcome of FLT3 mutated AML with diverse mutational profiles. Hence, a randomized trial has been initiated of standard chemotherapy combined with either crenolanib or midostaurin in newly diagnosed patients with FLT3-mutant AML (NCT03258931). Table. Table. Disclosures Goldberg: AROG: Research Funding; Pfizer: Research Funding; Celgene: Research Funding; Abbvie: Research Funding. Collins:Arog Pharmaceuticals: Research Funding; Celgene Corporation: Research Funding; Bristol Myers Squibb: Research Funding; Agios: Research Funding. Stone:Ono: Consultancy; Novartis: Consultancy, Research Funding; Agios: Consultancy, Research Funding; Argenx: Other: Data and Safety Monitoring Board; Arog: Consultancy, Research Funding; Merck: Consultancy; Fujifilm: Consultancy; Jazz: Consultancy; Orsenix: Consultancy; Astellas: Consultancy; Celgene: Consultancy, Other: Data and Safety Monitoring Board, Steering Committee; AbbVie: Consultancy; Amgen: Consultancy; Otsuka: Consultancy; Pfizer: Consultancy; Sumitomo: Consultancy; Cornerstone: Consultancy. Walter:Actinium Pharmaceuticals, Inc: Other: Clinical Trial support , Research Funding; Amgen Inc: Other: Clinical Trial Support, Research Funding; Amphivena Therapeutics, Inc: Consultancy, Other: Clinical Trial Support, Research Funding; Aptevo Therapeutics, Inc: Consultancy, Other: Clinical Trial Support, Research Funding; Covagen AG: Consultancy, Other: Clinical Trial Support, Research Funding; Boehringer Ingelheim Pharma GmbH & Co. KG: Consultancy; Pfizer, Inc: Consultancy; Seattle Genetics, Inc: Consultancy, Other: Clinical Trial Support, Research Funding. Wang:Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy; Jazz: Speakers Bureau; Jazz: Speakers Bureau; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Novartis: Speakers Bureau. Tallman:AROG: Research Funding; AbbVie: Research Funding; Orsenix: Other: Advisory board; Daiichi-Sankyo: Other: Advisory board; ADC Therapeutics: Research Funding; Cellerant: Research Funding; BioSight: Other: Advisory board.
10
Goldberg, Stuart L., Lei Chen, Solveig G. Ericson, Alexander R. Macalalad, Annie Guerin, Nathan Liu, Michael Kaminsky, and Eric Qiong Wu. "Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey." Blood 120, no. 21 (November 16, 2012): 1685. http://dx.doi.org/10.1182/blood.v120.21.1685.1685.
Full textAbstract:
Abstract Abstract 1685 Background: Molecular monitoring is recognized as an important part of evaluating treatment response in Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (Ph+ CML-CP). The latest guidelines from the National Comprehensive Cancer Network (NCCN) recommend quantitative polymerase chain reaction (QPCR) testing in the first 3 months with a goal of <10% Bcr-Abl transcripts using the international scale (IS), and then testing every 3 months to achieve at some point and maintain a 3 log reduction in transcripts (Major Molecular Response). Regular molecular monitoring provides an opportunity to detect resistance or adherence problems early. However, it remains unknown how patterns of use of molecular monitoring impact long term outcomes in non-research community settings. Methods: Community physicians who treat CML patients were invited to retrospectively submit information on Ph+ CML-CP patients in their practice who were ≥18 years old when started on first-line imatinib between 2006–2011 and who had ≥6 months of follow-up. Patients enrolled in clinical trials were excluded. Clinical characteristics at treatment initiation were collected. For each 3 month period after treatment initiation while the patient was on tyrosine kinase inhibitor (TKI) therapy, information was collected on molecular monitoring performed to assess treatment response. Information on death and progression to accelerated phase or blast crisis was collected over the entire follow-up period. Patients were grouped by the average number of QPCR tests received on TKI therapy (scaled to rate per year): the 0 tests group if they never had a QPCR test; the 1–2 tests group if they had on average more than 0 but 2 or less QPCR tests/year; and the 3–4 tests group if they had on average more than 2 but 4 or less QPCR test/year. Progression, mortality, and combined progression/mortality rates were reported for each group. In addition, Cox proportional hazards models were used to test the association between progression and progression-free survival and the average number of QPCR tests per year, controlling for the average number of cytogenetic tests per year, and for potential confounders including age, race, initial imatinib dose, Sokal score, and enlarged spleen at diagnosis. Results were reported as hazard ratios (HR) with 95% confidence intervals (CI). Results: 38 hematologists and oncologists from community practices throughout the US submitted information on 402 patients initiated on first-line imatinib. Patients were followed retrospectively for a median duration of 36 months. Of these, 52 (13%) had no molecular monitoring, 164 (41%) had 1–2 tests/year, and the remaining 186 (46%) had 3–4 tests/year. The figure below shows progression, mortality, and progression/mortality by frequency of molecular testing. The progression/mortality rates tended to decrease with the number of tests received. Adjusting for cytogenetic testing frequency and potential confounders aside from the Sokal score, a higher average number of QPCR tests per year was significantly associated with a lower rate of progression and longer progression-free survival. Each additional QPCR test per year significantly decreased the risk of progression by 45% (HR=0.55; CI [0.35, 0.87], p=0.011), and progression/mortality by 48% (HR=0.52; CI [0.35, 0.79], p=0.002]. Since 48% of patients did not have a reported Sokal score at diagnosis, a separate analysis was done to also adjust for the Sokal score among those without missing data, with nearly identical results. Conclusions: Ph+ CML-CP patients who underwent QPCR testing every 3–4 months experienced decreased progression and longer progression-free survival compared to those patients monitored less frequently, with the impact of molecular monitoring being independent of the frequency of cytogenetic testing. It is possible that molecular monitoring identifies impending treatment failure earlier and enables adjustment of therapy before hematologic and cytogenetic failure occur. This analysis underscores the value of molecular monitoring every 3 months for Ph+ CML-CP patients on TKI therapy and also demonstrates that a significant number of Ph+ CML-CP patients are not undergoing QPCR at the frequencies recommended in published guidelines. Additional community based education on CML monitoring is needed to assure optimal outcomes. Disclosures: Goldberg: Novartis Oncology: Research Funding, Speakers Bureau. Chen:Novartis Oncology: Employment, Own stock in Novartis Other. Ericson:Novartis Pharmaceuticals Corp: Employment, Own stock in Novartis Other. Macalalad:Analysis Group, Inc.: Consultancy, Employment, I am an employee of Analysis Group, Inc, which has received consulting fees from Novartis Pharmaceuticals Other, Research Funding. Guerin:Analysis Group, Inc.: Consultancy, Employment, I am an employee of Analysis Group, Inc, which has received consulting fees from Novartis Pharmaceuticals Other, Research Funding. Liu:Analysis Group, Inc.: Consultancy, Employment, I am an employee of Analysis Group, Inc, which has received consulting fees from Novartis Pharmaceuticals Other, Research Funding. Kaminsky:Analysis Group, Inc.: Consultancy, Employment, I am an employee of Analysis Group, Inc, which has received consulting fees from Novartis Pharmaceuticals Other, Research Funding. Wu:Analysis Group, Inc.: Consultancy, Employment, I am an employee of Analysis Group, Inc, which has received consulting fees from Novartis Pharmaceuticals Other, Research Funding.
Dissertations / Theses on the topic "Golder Associates Inc"
1
Krugh, Lisa S. "Report on a MTSC Internship at Golder Associates Inc." Miami University / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=miami1258382636.
Full textBooks on the topic "Golder Associates Inc"
1
Roberts, Benjamin. Sex, Drugs and Rock 'n' Roll in the Dutch Golden Age. NL Amsterdam: Amsterdam University Press, 2017. http://dx.doi.org/10.5117/9789462983021.
Full textAbstract:
Binge drinking and illicit sex were just as common in the Dutch Golden Age as they are today, if not more so. Sex, Drugs and Rock 'n' Roll in the Dutch Golden Age is a compelling narrative about the generation of young men that came of age in the Dutch Republic during the economic boom of the early seventeenth century. Contrary to their parents' wishes, the younger generation grew up in luxury and wore extravagant clothing, grew their hair long, and squandered their time drinking and smoking. They created a new youth culture with many excesses; one that we today associate with the counterculture generation of the 1960s. With his engaging storytelling style and humorous anecdotes, Roberts convincingly reveals that deviant male youth behavior is common to all times, especially periods when youngsters have too much money and too much free time on their hands.
2
McDermott, Christopher Warren. An internship with Goldberg-Zoino and Associates, Inc. 1986.
Find full text
3
Mee, Jon. The Revolutionary Decade. Edited by David Duff. Oxford University Press, 2018. http://dx.doi.org/10.1093/oxfordhb/9780199660896.013.2.
Full textAbstract:
This chapter examines the literature of the controversy over the French Revolution. It discusses the polemical texts that contributed directly to the controversy associated with Burke, Godwin, Paine, and Wollstonecraft, but also the culture wars that perpetuated it in terms of the novel, poetry, and the theatre. In the 1790s, some of the great names associated with Romanticism came to literary maturity, Blake, Coleridge, and Wordsworth among them. The chapter reminds readers that it was a golden age of satire as a consequence of the ideological conflict, but also a decade when the definitions of literature and culture entered a period of crisis and redefinition.
4
Marmysz, John. Yukio Mishima and the Return to the Body. Edinburgh University Press, 2018. http://dx.doi.org/10.3366/edinburgh/9781474424561.003.0013.
Full textAbstract:
In this chapter, the life, work and philosophy of the Japanese author Yukio Mishima are explored. It is argued that the most interesting and profound properties of Mishima’s thought, his writings, and of the films associated with his thought and writings, are those that leave us with a sense of the open-ended struggle involved in his effort to define himself. The chapter examines some of Mishima’s most important literary works – including Confessions of a Mask, Temple of the Golden Pavilion, The Sailor Who Fell From Grace With the Sea, Patriotism, and The Sea of Fertility – as well as cinematic interpretations of these works by directors such as Paul Schrader, Lewis John Carlino, and Yukio Mishima himself. It is concluded that for Mishima, the defeat of nihilism was ultimately realized in his suicide by ritual seppuku.
5
Holes, Clive. Orality, Culture, And Language. Edited by Jonathan Owens. Oxford University Press, 2013. http://dx.doi.org/10.1093/oxfordhb/9780199764136.013.0012.
Full textAbstract:
This article explores the relationship between linguistic form and function in the varying cultural landscapes of the contemporary Arabic-speaking world, including spontaneous speech, the contemporary electronic media (television, radio, the Internet), cinema, theater, and traditional performed oral literature, which have been revived and “reinvented.” It is shown that the relationship between orality and language in Arabic is complex. The layman’s mental landscape is of a “high,” literary, codified variety of the language strongly identified with a unifying religion (Islam) and a “golden age” of past imperial and literary glories, carrying great cultural prestige; and a “low,” chaotic (often regarded as grammarless) but homely variety associated with domesticity, intimacy, and the daily round. The emotional resonances of the two varieties are and always have been different. Consequently, they have, through the ages, occupied separate functional niches in all linguistically mediated communication, be it speech, writing, song, poetry, cinema, or theater.
6
Bolsover, Gillian. China. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190931407.003.0010.
Full textAbstract:
Computational propaganda is a growing concern in Western democracies, with evidence of online opinion manipulation orchestrated by robots, fake accounts, and misinformation in many recent political events. China, the country with the most sophisticated regime of Internet censorship and control in the world, presents an interesting and under-studied example of how computational propaganda is used. This chapter summarizes the landscape of current knowledge in relation to public opinion manipulation in China. It addressees the questions of whether and how computational propaganda is being used in and about China, whose interests are furthered by this computational propaganda; and what is the effect of this computational propaganda on the landscape of online information in and about China. It also addresses the issue of how the case of computational propaganda in China can inform the current efforts of Western democracies to tackle fake news, online bots, and computational propaganda. This chapter presents four case studies of computational propaganda in and about China: the Great Firewall and the Golden Shield project; positive propaganda on Twitter aimed at foreign audiences; the anti–Chinese state bots on Twitter; and domestic public opinion manipulation on Weibo. Surprisingly, I find that there is little evidence of automation on Weibo and little evidence of automation associated with state interests on Twitter. However, I find that issues associated with anti-state perspectives, such as the pro-democracy movement, contain a large amount of automation, dominating Chinese-language information in certain hashtags associated with China and Chinese politics on Twitter.
7
Selva-O’Callaghan, Albert, and Ernesto Trallero-Araguás. Association with malignancy. Edited by Hector Chinoy and Robert Cooper. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198754121.003.0008.
Full textAbstract:
Nearly one-third of adult myositis patients additionally have some type of associated cancer, observed most commonly in dermatomyositis patients. The relationship between cancer and myositis is generally considered a paraneoplastic phenomenon; that is, in one way or another, the two conditions are related. A parallel course of the diseases—myositis improves after cancer is cured and when cancer recurs, myositis worsens—is considered a classical paraneoplastic criterion. Nevertheless, this parallel clinical course does not always occur in true cancer-associated myositis, or perhaps it cannot be seen because of the interference of therapy. Based on epidemiologic studies, the current gold standard for the diagnosis of cancer-associated myositis is a temporal criterion: diagnosis of the two diseases within a 3-year period, although to a certain extent, this is an arbitrary standard.
8
Davey, Patrick, Sherif Gonem, Salman Siddiqui, and David Sprigings. Chronic obstructive pulmonary disease. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0134.
Full textAbstract:
The Global Initiative for Chronic Lung Disease (GOLD) states that ‘chronic obstructive pulmonary disease (COPD), a common preventable and treatable disease, is characterised by persistent airflow limitation that is usually progressive and is associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles and gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.’
9
Duckett, Victoria. Nullius in Verba. University of Illinois Press, 2017. http://dx.doi.org/10.5406/illinois/9780252039669.003.0002.
Full textAbstract:
This chapter challenges the notion that Sarah Bernhardt mouthed her lines on film due to her inability to act in a fittingly naturalistic way for film, and that her famous “golden voice” is brutally denied in a media that gives us the spectacle of an actress mouthing lines that we cannot hear. The chapter explains why an actress who was famous for her voice and gesture acts on silent film in terms of art nouveau acting, changes in visual literature, and the ongoing use of musical accompaniment—all of which allow us to reinterpret Bernhardt's relationship to the silent screen. It argues that Bernhardt's films record her gestural fame on the live stage, and that this fame was associated with her use of the spiral as a structuring device for action. It shows that the music that accompanied Bernhardt's films served the same purpose as it did on the live stage—to develop and expand the emotional resonance of her performance.
10
Bissell, Lesley-Anne, Dwomoa Adu, and Paul Emery. The patient with rheumatoid arthritis, mixed connective tissue disease, Sjögren syndrome, or polymyositis. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0166.
Full textAbstract:
Renal disease is a well-recognized cause of ill health and death in rheumatoid arthritis. Three broad categories of renal disease occur. The first—and by far the most common—arises from the nephrotoxicity of the drugs used in the treatment of arthritis, particularly with non-steroidal anti-inflammatory drugs. Disease-modifying antirheumatic drugs such as gold and D-penicillamine may lead to proteinuria and a glomerulonephritis in 10–30% of patients. Ciclosporin is associated with significant nephrotoxicity and hypertension. A second major but diminishing cause of renal disease in rheumatoid arthritis is amyloidosis. Thirdly, rheumatoid arthritis may be associated with the development of glomerulonephritis. The main types described are a mesangial proliferative glomerulonephritis with or without immunoglobulin A deposits, a membranous nephropathy, and a focal segmental necrotizing glomerulonephritis of the vasculitic type.Renal disease in mixed connective tissue disease and polymyositis is infrequent, but the former can be associated with a membranous and mesangial proliferative glomerulonephritis.Sjögren syndrome is rarely associated with clinically significant renal disease, but patients can present with proteinuria, acidosis, or hyperchloraemia. Interstitial nephritis and immune complex glomerulonephritis reflect the exocrinopathy and circulating immune complex disease pathognomonic of Sjögren syndrome. Evidence for effective treatment of the renal complications is lacking. Corticosteroids and cyclophosphamide are most commonly used, with newer biological drugs, such as rituximab, showing promise.
Book chapters on the topic "Golder Associates Inc"
1
Cagliero, Julie, Karl Huet, and Mariko Matsui. "Use of Golden Syrian Hamster as an Animal Model to Study Leptospirosis-Associated Immune Responses." In Methods in Molecular Biology, 243–55. New York, NY: Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-0459-5_22.
Full text
2
Dessertine, Anna. "Spatializing Social Change: Artisanal and Small-Scale Gold Mining in Upper Guinea." In Methodological Approaches to Societies in Transformation, 213–35. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-65067-4_9.
Full textAbstract:
AbstractThis chapter proposes a spatial perspective on the analysis of social change in the making via a study of artisanal and small-scale gold-mining sites in Guinea based on twenty-two months of fieldwork between 2011 and 2019 in the region of Upper Guinea, where increasing numbers of inhabitants have been circulating between artisanal and small-scale mining sites to search for gold since the price of gold rose between 2008 and 2012. The chapter starts by discussing artisanal and small-scale mining spaces through the notion of hotspots of transition, insisting on their liminal character. This liminality is analyzed as a spatial framework in which new opportunities emerge regarding gender—women’s adoption of what is considered masculine behavior, for instance—and where instantaneity is more privileged than continuity in some actions, such as those associated with consumption. More generally, it shows how the potential for change in artisanal and small-scale mining spaces is closely linked to their ephemeral nature. The relationship between space and temporality is more explicitly discussed in the second part of the chapter, which explores how the ephemerality of artisanal and small-scale mining spaces has recently been challenged by the Guinean government’s move to control mining mobility and fix mining sites spatially by delimiting legal mining territories. Since 2015–2016, multiple military operations have been conducted to expel miners from land for which the Guinean State has given industrial companies legal permits to prospect for and mine gold. This part of the chapter analyzes the socio-spatial consequences of this situation and shows that perceptions of time and of social change are constructed by the forms that space take.
3
"16 Ian Borden (associate professor of theatre studies), Johnny Carson School of Theatre and Film, University of Nebraska." In Social Justice in Spanish Golden Age Theatre, 232–36. University of Toronto Press, 2020. http://dx.doi.org/10.3138/9781487536671-020.
Full text
4
Gordon, Kimberley, and Jill Auten. "The Encore Chapter." In Advances in Early Childhood and K-12 Education, 157–72. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-5667-1.ch011.
Full textAbstract:
As tens of thousands of Baby Boomers leave the workplace each month, the stark reality of retirement is often accompanied by an overwhelming sense of dread. Retiring from employment at the age of 65 is often not practical for those without ample financial resources. Many will retire outright while others seek employment in an encore career in roles that are fulfilling and typically require less of a time commitment. Identifying plans for the final chapter in life is essential for contentment and critical for staving off declining physical and mental health. When senior adults understand the nuances of adult learning and the myriad theories associated with lifespan development, they are equipped with fundamental tools to help them navigate the golden years. This chapter provides readers with essential tools to aid adults experiencing significant life changes especially those embarking on their encore chapter.
5
Clark, Robin D., and Cynthia J. Curry. "Hirschsprung Disease." In Genetic Consultations in the Newborn, edited by Robin D. Clark and Cynthia J. Curry, 167–70. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780199990993.003.0025.
Full textAbstract:
This chapter reviews background information about the incidence, risk factors, sex ratio, genetics, family history, recurrence risk, and epidemiology of the various types of isolated and syndromic Hirschsprung disease. Distinctions that characterize long segment, short segment, zonal, total colonic, and total intestinal aganglionosis are reviewed. The discussion on the differential diagnosis of Hirschsprung disease summarizes its common causes, including chromosome anomalies (Down syndrome and recurrent microdeletions), and Mendelian traits associated with isolated disease and syndromic aganglionosis with non-GI malformations. This chapter includes gives recommendations for evaluation and management. A clinical case presentation features an SGA microcephalic infant who failed to pass meconium with Goldberg–Shprintzen syndrome.
6
Holmwood, John, and Therese O’Toole. "A plot to Islamicise schools?" In Countering Extremism in British Schools? Policy Press, 2017. http://dx.doi.org/10.1332/policypress/9781447344131.003.0001.
Full textAbstract:
This introductory chapter provides an overview on the events in Birmingham that came to the public attention in March 2014 involving an alleged plot by conservative and hardline Sunnis to Islamicise a number of state-funded schools where there were significant numbers of Muslim pupils. Attention was focused on one particular school, Park View Academy, and its associated Park View Educational Trust (PVET), incorporating two other schools, Nansen Primary and Golden Hillock secondary. The affair also drew in many others who were suspected of extremist activity — with 21 schools in Birmingham subjected to snap Office for Standards in Education (Ofsted) inspections and included in the various inquiries into the affair. The government cites the 'plot' in its argument about the need to develop a new counter-extremism strategy that confronts extremist ideology and not just threats of violence. However, the Kershaw Report and some other commentators argue that there was, in fact, no evidence of extremism.
7
Sarhan, Nael M., Adela McMurray, and Foula Kopanidis. "The Challenges and Opportunities in Addressing the Needs of Middle Eastern Tourists." In Emerging Research on Islamic Marketing and Tourism in the Global Economy, 136–59. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-6272-8.ch007.
Full textAbstract:
This chapter identifies and discusses the specific needs of Middle Eastern tourists visiting the Gold Coast, Queensland Australia. Based on empirical data collected through a qualitative study, self-administered questionnaires (N = 500) were distributed to Middle Eastern tourists who visited the Gold Coast and stayed at Gold Coast accommodation for at least one night. The 305 responses (61 percent response rate), generated a total number of 461 multiple responses. Content Analysis identified key themes and sub-themes associated with Islamic religious beliefs. The findings showed that the management of the Gold Coast accommodation sector had a distinct lack of information and understanding of Middle Eastern tourists' needs. This chapter provides useful managerial and marketing recommendations, including suggested best practices, to hoteliers who provide accommodation services to international tourists, such as Middle Eastern tourists, and contributes to the limited knowledge on Islamic marketing. This in turn potentially contributes to the increased success of the tourism industry in developed countries such as Australia.
8
Hinton, Carmelita. "Evil Dragon, Golden Rodent, Sleek Hound: The Evolution of Soushan Tu Paintings in the Northern Song Period." In The Zoomorphic Imagination in Chinese Art and Culture. University of Hawai'i Press, 2016. http://dx.doi.org/10.21313/hawaii/9780824846763.003.0006.
Full textAbstract:
In soushan tu paintings, a seated deity commands ferocious soldiers who search wooded mountains to expel demons in animal forms. It is commonly believed that soushan tu originated from legends of Erlang, a river deity from Guankou, Sichuan who appears as the seated commander in some post Northern Song examples. Earlier textual and pictorial evidence, however, contradicts this assumption. This essay traces the changing identities of the commander during the tenth and eleventh centuries and how certain animals associated with them became part of the pictorial repertoire. Rather than illustrating a pre-existing story with fixed characters, the mountain searches depict a symbolic conflict. The deity stands as the figure of authority, while the demonic animals represent the disruptive forces of dissent and chaos that threaten his control. Characters once considered demons come to occupy the role of commander, reflecting the contested nature of the categories of “demon” and “deity.”
9
Henama, Unathi Sonwabile. "Tourism as a Neoliberal Economic Messiah." In Advances in Hospitality, Tourism, and the Services Industry, 29–51. IGI Global, 2019. http://dx.doi.org/10.4018/978-1-5225-6983-1.ch003.
Full textAbstract:
Tourism has grown since the democratic transition in 1994. The growth of tourism has been so spectacular that today, tourism is regarded as the new gold, as it is South Africa's number one export. For the past 24 years, tourism's growth rate has always exceeded the national growth rate of the country. The sustained growth of tourism caught the attention of policy makers and private investors. The growth of tourism has mitigated the decline of mining, especially gold mining, that was the primary driver of the economy for decades. The economy of South Africa is suffering from a decline in the commodity prices, and the shedding of jobs in mining. The rise of tourism occurred when the economic fortunes were dampened by the decline of mining and agriculture, leading to widespread poverty associated with unemployment. Tourism has become an economic messiah. The literature review adds to a paucity of academic gaze on the tourism industry in South Africa.
10
Nair, Amla, and Sahar Joel D'Souza. "The Impact of Indian Consumer's Mood on Their Perception for the Jewelry Brand Tanishq." In Advances in Marketing, Customer Relationship Management, and E-Services, 179–99. IGI Global, 2019. http://dx.doi.org/10.4018/978-1-5225-5690-9.ch008.
Full textAbstract:
India's fascination with jewelry goes way back to 5000 years with gold being the widely preferred choice for ornamental and investment purposes. Seventy-five percent of the Indian gold market is currently dominated by non-branded players. The existence of age-old loyalty towards family jewelers made it difficult for branded jewelers to break through the market. Hence, this research paper attempts to examine the consumer's perception towards one of the biggest brands in Indian jeweler Tanishq. Being a TATA brand, it is immediately associated with the respect that the brand brings with it, creating great brand salience. Tanishq penetrates varied cultures and life stages to deliver efficient customer service, garnering loyalty. However, Tanishq has positioned itself as a premium brand, commanding high making charges for its designs, which tends to alienate certain classes of society, and its sub-brands are overshadowed by the parent brand. With exemplary designs and customer service, Tanishq does make a mark on the Indian population, making it an aspirational brand.
Conference papers on the topic "Golder Associates Inc"
1
Pata, Joosep, and Alan H. Tkaczyk. "Isotope-Based Analysis of Nuclear Waste Repository Performance." In 18th International Conference on Nuclear Engineering. ASMEDC, 2010. http://dx.doi.org/10.1115/icone18-30173.
Full textAbstract:
It is necessary to consider the complexities of both natural and engineered components of a nuclear waste repository since fission products and minor actinides remain harmful to the environment for tens of thousands of years. In safety and performance assessments often used in decision-making about repository designs, the effect of uncertain initial guesses on the models’ output must be understood. As the necessary safe times and hence the simulated times are often in the order of magnitude of hundreds of thousands of years, uncertain initial values become increasingly important. To minimize the danger from high-level radioactive waste and to make informed decisions over designs, sensitivity analysis of the models used should be performed. The Simplified Total System Performance Assessment (STSPA) model developed by Golder Associates Inc., Booz-Allen Hamilton, Stone and Webster and the University of Nevada Reno and used in the Yucca Mountain nuclear waste repository performance assessment is analyzed for sensitivity by varying the activities of technetium-99 and iodine-129 by several orders of magnitude. The resultant dose to a maximally-exposed individual over time periods of 100,000 and 1,000,000 years is compared to the relevant regulatory limits. Incorrect estimates can be seen to have large effects on the behavior of the model while the method used allows conclusions to be drawn about the robustness of the model.
2
Karekal, Shivakumar, M. Rao, and Chinnappa Srinivasan. "Mining-Associated Seismicity in Kolar Gold Mines—Some Case Studies Using Multifractals." In Sixth International Symposium on Rockburst and Seismicity in Mines. Australian Centre for Geomechanics, Perth, 2005. http://dx.doi.org/10.36487/acg_repo/574_72.
Full text
3
Abumazwed, Ahmed, Wakana Kubo, Takuo Tanaka, and Andrew G. Kirk. "Simulation and experimental studies on plasmonic properties associated with gold nanofin array on a polymer film." In 2013 IEEE Photonics Conference (IPC). IEEE, 2013. http://dx.doi.org/10.1109/ipcon.2013.6656567.
Full text
4
Li, Zijia, and Andreas Mueller. "Mechanism Singularities Revisited From an Algebraic Viewpoint." In ASME 2019 International Design Engineering Technical Conferences and Computers and Information in Engineering Conference. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/detc2019-97742.
Full textAbstract:
Abstract It has become obvious that certain singular phenomena cannot be explained by a mere investigation of the configuration space, defined as the solution set of the loop closure equations. For example, it was observed that a particular 6R linkage, constructed by combination of two Goldberg 5R linkages, exhibits kinematic singularities at a smooth point in its configuration space. Such problems are addressed in this paper. To this end, an algebraic framework is used in which the constraints are formulated as polynomial equations using Study parameters. The algebraic object of study is the ideal generated by the constraint equations (the constraint ideal). Using basic tools from commutative algebra and algebraic geometry (primary decomposition, Hilbert’s Nullstellensatz), the special phenomenon is related to the fact that the constraint ideal is not a radical ideal. With a primary decomposition of the constraint ideal, the associated prime ideal of one primary ideal contains strictly into the associated prime ideal of another primary ideal which also gives the smooth configuration curve. This analysis is extended to shaky and kinematotropic linkages, for which examples are presented.
5
Mayton, Alan G., and Brian Y. Kim. "Evaluation of i-Pod App to Assess Whole-Body Vibration and Seat Transmissibility on Mobile Mining Equipment." In ASME 2018 International Design Engineering Technical Conferences and Computers and Information in Engineering Conference. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/detc2018-86217.
Full textAbstract:
Researchers at the National Institute for Occupational Safety and Health (NIOSH) performed a pilot study focusing on the measurement accuracy of a mobile iOS application (app) to assess whole-body vibration (WBV) and seat performance on mobile mining equipment. The major objectives of this study were to assess the accuracy of an iPod app and determine if a pair of iPods running the iPod app were suitable to measure SEAT (Seat Effective Amplitude Transmissibility) value. The goal is to recommend a simple method to determine when a vehicle seat may need to be repaired, replaced, or adjusted. The study showed that the iPod app has the potential to serve as a low-cost tool to estimate WBV exposures to operators of mobile mining equipment. The study results were similar to those obtained by Burgess-Limerick et al. for operator WBV exposures on mining equipment. In contrast, an effort to examine seat performance using the mobile app showed greater variation between the app and the precision Siemens/LMS system selected as the “gold standard.” When comparing the Siemens/LMS and iPod pair systems, SEAT values calculated using weighted-root-mean-square acceleration (aw) resulted in a mean percent difference of 8.5±7.9%, whereas those calculated using vibration dose value (VDV) resulted in a mean percent difference of 5.5±4.4%. Additional data collection is necessary to determine what factors may be associated with this variance.
Reports on the topic "Golder Associates Inc"
1
Ye, Binglin, Shuling Li, Fengqi Sun, Youfu Fan, Weiguo Chen, and Xiangfu Wang. Effect of full-endoscopic cervical laminectomy and decompression versus anterior cervical decompression with fusion in the treatment of patients with cervical spondylotic myelopathy: A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2021. http://dx.doi.org/10.37766/inplasy2021.8.0034.
Full textAbstract:
Review question / Objective: This systematic review aims to comprehensively assess the efficacy and safety of full-endoscopic cervical laminectomy and decompression versus anterior cervical decompression with fusion in treating cervical spondylotic myelopathy (CSM) patients. Condition being studied: Cervical spondylotic myelopathy (CSM) is a degenerative disease associated with cervical cord compression, which has increased significant health-related social costs and derived disabilities. Anterior cervical discectomy and fusion (ACDF) is the "gold standard" for the treatment of CSM. However, the application of ACDF may cause some complications. Recently, full-endoscopic cervical laminectomy and decompression have shown potential therapeutic effects for CSM. However, no systematic review or meta-analysis has focused on the effects of full-endoscopic cervical laminectomy and decompression in the treatment of CSM. This systematic review aims to comprehensively assess the efficacy and safety of full-endoscopic cervical laminectomy and decompression versus anterior cervical decompression with fusion in treating CSM patients.